Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma
Chronic Lymphocytic LeukemiaLymphoma1 moreAllogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed...
Multiple MyelomaThe primary objective of this study is to determine the rate of molecular remissions (MolR) assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone (Vel/Dex) prior to high-dose therapy with melphalan and autologous stem cell transplantation (HDT-ASCT), and after HDT-ASCT in patients with multiple myeloma.
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous...
Multiple MyelomaTo assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation...
Multiple MyelomaHematopoietic reconstitution defined by a neutrophils number > 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number > 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.
Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by...
MyelomaDonor mobilization : Donor will be mobilized with G-CSF (Granocyte) sub-cutaneous 10 µg/kg/day during 5 to 6 days. Hematopoïetic Stem Cell Harvest: By 1, 2, or 3 aphaeresis, a number of 4 x 106 cellules CD34+ /kg is required. If the CD34+ >= 2 and <= 4x106/kg: the center must decide on the strategy Decision. In case of insufficient graft : a Bone Marrow Harvest is recommended Conditioning : Fludarabine - Busulfan - ATG D-5 : Fludarabine (30 mg/m²) D-4 : Fludarabine (30 mg/m²)+ Busilvex (0,8 mg/kg every 6 h) D-3 : Fludarabine (30 mg/m²)+ Busilvex (0,8 mg/kg every 6 h) D-2 : Fludarabine (30 mg/m²) + ATG (Genzyme) (2.5 mg/Kg) D-1 : Fludarabine (30 mg/m²) + ATG (Genzyme) (2.5 mg/Kg) GVHD Prophylaxis: CsA alone at 3 mg/ kg + Methotrexate D1, D3 and D6 only in case of minor ABO incompatibility and with an anti A/B antibodies titer> 1/32. Transplant : HSC at D0 • 3 months after Transplantation : Disease Evaluation : If CR : Supervision. Then if progression: 4 cycles of Bortezomib. If no CR : Bortezomib (4 cycles) • Evaluation after Bortezomib cycles If CR : Supervision. Then, if progression and no GvHD : DLI If no RC and no GVHD : DLI
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating...
Multiple Myeloma and Plasma Cell NeoplasmThe purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease.
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously...
Multiple MyelomaThe purpose of this study is to determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated...
Multiple MyelomaThis study has been designed to evaluate whether combination chemotherapy and "anti-angiogenesis" therapy with thalidomide is equal or superior to autologous transplantation for the treatment of multiple myeloma.
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple...
Multiple MyelomaThe purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic profiles of the 2 doses of VELCADE (bortezomib) for Injection. Patients who volunteer to participate in the pharmacogenetic portion of the study, an additional blood sample will be collected before the Cycle 1 Day 1 dose of bortezomib to assess the genotype of drug metabolizing enzymes.
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic...
Multiple MyelomaHodgkin Lymphoma2 moreThe purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by the standard blood cancer treatment of chemotherapy and autologous hematopoietic cell transplantation. This study will also look at whether romiplostim can decrease the number of times the participant needs to return to the clinic for platelet transfusions to treat their low platelet count. In addition, the researchers will determine how safe it is to give romiplostim to people with blood cancer who have received treatment with chemotherapy and autologous hematopoietic cell transplantation.